275.3500 -0.40 (-0.15%)
NSE Jul 16, 2026 15:31 PM
Volume: 1.3M
 

275.35
-0.15%
Dynamic Levels
Marksans R&D; capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development and conducting stability studies. The company has a team of over 50 experienced scientists specializing in formulation development and analytical development. The conpany has possessed end-to-end capabilities from Lab scale development to Pilot scale up and from commercializing the product for large...
FII/FPI have increased holdings from 8.13% to 16.76% in Mar 2026 qtr.
More from Marksans Pharma Ltd.
Recommended